Norpramin (desipramine hydrochloride) Lawsuit

Schmidt & Clark, LLP is No Longer Taking These Cases - If you feel that you may have a potential case, we urge you to contact another law firm adequately suited to handle your case.

On December 2, 2009 the U.S. Food & Drug Administration (FDA) in association with Sanofi-Aventis notified healthcare professionals that there were substantial changes made to the Warnings and Overdosage sections in the labeling for the popular antidepressant Norpramin (generic: desipramine hydrochloride).

The manufacturer has issued the following warning:

Extreme caution should be used when this drug is given to patients who have a family history of sudden death, cardiac dysrhythmias, and cardiac conduction disturbances; and that seizures precede cardiac dysrhythmias and death in some patients.

Additional Resources:

Awards & recognition